CDKN2A and pulmonary fibrosis: To determine whether the PCLS screen correlated with in vivo activity against p16Ink4a+ fibroblasts, we set up an in vivo validation step where each of the candidate compounds tested in PCLS (XL888, ganetespib, TSA, fimepinostat, and dacinostat) was administered in our preclinical model of lung fibrosis and compared against vehicle-treated control animals (each compound required a different vehicle cohort because each is formulated differently with different routes of administration).